Adoption and Implementation of Medications in Addiction Treatment Programs

被引:144
作者
Knudsen, Hannah K. [1 ,2 ]
Abraham, Amanda J. [3 ,4 ]
Roman, Paul M. [3 ,4 ]
机构
[1] Univ Kentucky, Coll Med, Dept Behav Sci, Lexington, KY 40536 USA
[2] Univ Kentucky, Coll Med, Ctr Drug & Alcohol Res, Lexington, KY 40536 USA
[3] Univ Georgia, Ctr Res Behav Hlth & Human Serv Delivery, Athens, GA 30602 USA
[4] Univ Georgia, Dept Sociol, Athens, GA 30602 USA
关键词
medications; implementation research; addiction treatment programs; SUBSTANCE-ABUSE TREATMENT; TREATMENT ORGANIZATIONS; INNOVATION ADOPTION; COUNSELOR ATTITUDES; STATED PREFERENCE; BUPRENORPHINE; NALTREXONE; PRIVATE; AVAILABILITY; SPECIALISTS;
D O I
10.1097/ADM.0b013e3181d41ddb
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Objectives: Little is known about the extent to which medications are being implemented as routine care in addiction treatment programs. This research describes medication adoption and implementation within the privately funded treatment sector. Methods: Face-to-face interviews were conducted with 345 administrators of a nationally representative sample of privately funded substance treatment organizations in the United States. Results: Rates of adoption of addiction treatment medications in private sector programs were lower than the adoption of psychiatric medications. Even when analyses were restricted to programs with access to physicians, adoption of each addiction treatment medication had occurred in less than 50% of programs. Within adopting programs, implementation was highly variable. Although approximately 70% of patients with cooccurring psychiatric diagnoses received psychiatric medications, rates of implementation of medication-assisted treatment for opioid dependence and alcohol use disorders were just 34.4% and 24.0%, respectively. Conclusions: Although previous research has documented higher rates of medication adoption in privately funded treatment programs, this study revealed that both adoption and implementation of pharmacotherapies to treat addiction remains modest. Future research should examine the different types of barriers to implementation, such as physician decision making, patient preferences, and system-level barriers stemming from financing and public policy.
引用
收藏
页码:21 / 27
页数:7
相关论文
共 32 条
[11]   Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence [J].
Kissin, Wendy ;
McLeod, Caroline ;
Sonnefeld, Joseph ;
Stanton, Arlene .
JOURNAL OF ADDICTIVE DISEASES, 2006, 25 (04) :91-103
[12]   The use of antidepressant medications in substance abuse treatment: The public-private distinction, organizational compatibility, and the environment [J].
Knudsen, Hannah K. ;
Ducharme, Lori J. ;
Roman, Paul M. .
JOURNAL OF HEALTH AND SOCIAL BEHAVIOR, 2007, 48 (02) :195-210
[13]   The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters [J].
Knudsen, Hannah K. ;
Ducharme, Lori J. ;
Roman, Paul A. .
DRUG AND ALCOHOL DEPENDENCE, 2007, 87 (2-3) :164-174
[14]  
Knudsen HK, 2007, PSYCHIAT SERV, V58, P55, DOI 10.1176/appi.ps.58.1.55
[15]   Early adoption of buprenorphine in substance abuse treatment centers: Data from the private and public sectors [J].
Knudsen, Hannah K. ;
Ducharme, Lori J. ;
Roman, Paul M. .
JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2006, 30 (04) :363-373
[16]   Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network [J].
Knudsen, Hannah K. ;
Abraham, Amanda J. ;
Johnson, J. Aaron ;
Roman, Paul M. .
JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2009, 37 (03) :307-312
[17]   Organizational predictors of pharmacological innovation adoption: The case of disulfiram [J].
Knudsen, HK ;
Roman, PM ;
Ducharme, LJ ;
Johnson, JA .
JOURNAL OF DRUG ISSUES, 2005, 35 (03) :559-573
[18]   Buprenorphine diffusion: the attitudes of substance abuse treatment counselors [J].
Knudsen, HK ;
Ducharme, LJ ;
Roman, PM ;
Link, T .
JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2005, 29 (02) :95-106
[19]   Modeling the use of innovations in private treatment organizations: The role of absorptive capacity [J].
Knudsen, HK ;
Roman, PM .
JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2004, 26 (01) :353-361
[20]   Characteristics of US substance abuse treatment facilities adopting buprenorphine in its initial stage of availability [J].
Koch, Alison L. ;
Arfken, Cynthia L. ;
Schuster, Charles R. .
DRUG AND ALCOHOL DEPENDENCE, 2006, 83 (03) :274-278